ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3218-3224

  Sham, Hing L ^a   Kempf, Dale J ^a   Molla, Akhteruzammen ^a   Marsh, Kennan C ^a   Kumar, Gondi N ^a   Chen, Chih Ming ^a   Kati, Warren ^a   Stewart, Kent ^a   Lal, Ritu ^a   Hsu, Ann ^a   Betebenner, David ^a   Korneyeva, Marina ^a   Vasavanonda, Sudthida ^a   McDonald, Edith ^a   Saldivar, Ayda ^a   Wideburg, Norm ^a   Chen, Xiaoqi ^a   Niu, Ping ^a   Park, Chang ^a   Jayanti, Venkata ^a   Grabowski, Brian ^a   Granneman, G Richard ^a   Sun, Eugene ^a   Japour, Anthony J ^a   Leonard, John M ^a   Plattner, Jacob J ^a   Norbeck, Daniel W ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 155704; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; N [1 BENZYL 3 HYDROXY 5 PHENYL 4 (5 THIAZOLYLMETHOXYFORMAMIDO)PENTYL]TETRAHYDRO ALPHA ISOPROPYL 2 OXO 1(2H) PYRIMIDINEACETAMIDE; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER MICROSOME METABOLISM; MALE; MONKEY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; RAT; VIRUS INHIBITION;

EID: 0031788930     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3218     Document Type: Article

References (29)

1. Cameron, D. W., M. Heath-Chiozzi, S. Danner, C. Cohen, S. Krabcik, C. Maurath, E. Sun, D. Henry, R. Rode, A. Potoff, and J. Leonard. 1998. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351:543-549.
2. Carrillo, A., K. D. Stewart, H. L. Sham, D. W. Norbeck, W. E. Kohlbrenner, J. M. Leonard, D. J. Kempf, and A. Molla. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:7532-7541.
3. Clumeck, N. 1997. Clinical benefit of saquinavir (SQV) plus zalcitabine (ddC) plus zidovudine (ZDV) in untreated/minimally treated HIV-infected patients, abstr. LB-4. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. American Society for Microbiology, Washington, D.C.
4. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. Gil Aguado, J. Garcia de Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333: 1528-1533.
5. Greco, W. R., and M. T. Hakala. 1979. Evaluation of methods for estimating the dissociation constant of tight binding inhibitors. J. Biol. Chem. 254: 12104-12109.
6. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Dayton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of 2 nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
7. Hirsch, M. S., and R. T. D'Aquila. 1993. Therapy for human immunodeficiency virus infection. N. Engl. J. Med. 328:1686-1695.
8. Hsu, A., R. Granneman, G. Witt, C. Locke, J. Denissen, A. Molla, J. Valdes, J. Smith, K. Erdman, N. Lyons, P. Niu, J.-P. Decourt, J.-B. Fourtillan, J. Girault, and J. M. Leonard. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
9. Kempf, D., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X.-P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
10. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
11. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 35:2209-2214.
12. Kempf, D. J., H. L. Sham, K. C. Marsh, C. A. Flentge, D. Betebenner, B. E. Green, E. McDonald, S. Vasavanonda, A. Saldivar, N. E. Wideburg, W. M. Kati, L. Ruiz, C. Zhao, L. Fino, J. Patterson, A. Molla, J. J. Plattner, and D. W. Norbeck. 1998. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 41: 602-617.
13. Kröhn, A., S. Redshaw, J. C. Ritchie, B. J. Graves, and M. H. Hatada. 1991. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J. Med. Chem. 34:3340-3342.
14. 13a. Kumar, G. Unpublished data.
15. 13b. Kumar, G., et al. Unpublished results.
16. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431.
17. Kumar, G. N., V. Jayanti, R. Lee, D. Whittern, J. Uchic, S. Thomas, P. Johnson, B. Grabowski, H. Sham, D. Betebenner, D. Kempf, and J. F. Denissen. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab. Dispos., in press.
18. Lal, R., A. Hsu, P. Chen, S. Dennis, T. El-Shourbagy, C. Locke, W. Lam, A. Japour, J. Leonard, G. R. Granneman, and E. Sun. 1997. Single dose pharmacokinetics of ABT-378 in combination with ritonavir, abstr. I-194, p. 279. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, K. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
20. 17a. Marsh, K., et al. Unpublished results.
21. Matayoshi, E. D., G. T. Wang, G. A. Krafft, and J. Erickson. 1990. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247:954-958.
22. Molla, A., G. R. Granneman, E. Sun, and D. Kempf. Antivir. Res., in press.
23. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
24. Molla, A., S. Vasavanonda, J. Denissen, G. Kumar, B. Grabowski, H. Sham, D. Norbeck, W. Kohlbrenner, J. Plattner, D. Kempf, and J. Leonard. Human serum attenuates the activity of protease inhibitors toward wild type and mutant human immunodeficiency virus. Virology, in press.
25. 21a. Park, C. Unpublished results.
26. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
27. Sham, H. L., C. Zhao, K. D. Stewart, D. A. Betebenner, S. Lin, C. H. Park, X.-P. Kong, J. Rosenbrook, W. T. Herrin, D. Madigan, S. Vasavanonda, N. Lyons, A. Molla, A. Saldivar, K. C. Marsh, E. McDonald, N. E. Wideburg, J. F. Denissen, T. Robins, D. J. Kempf, J. J. Plattner, and D. W. Norbeck. 1996. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. J. Med. Chem. 39:392-397.
28. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.
29. Tong, L., S. Pav, S. Mui, D. Lamarre, C. Yoakim, P. Beaulieu, and P. C. Anderson. 1995. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure 3: 33-40.